DOCSLIB.ORG

Kent Academic Repository Full Text Document (Pdf)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Kent Academic Repository Full Text Document (Pdf) Kent Academic Repository Full text document (pdf) Citation for published version Mathie, Alistair and Veale, Emma L (2007) Therapeutic potential of neuronal two-pore domain potassium-channel modulators. Review of: therapeutic modulators by UNSPECIFIED. Current opinion in investigational drugs (London, England : 2000), 8 (7). pp. 555-62. ISSN 1472-4472. DOI Link to record in KAR https://kar.kent.ac.uk/75925/ Document Version Publisher pdf Copyright & reuse Content in the Kent Academic Repository is made available for research purposes. Unless otherwise stated all content is protected by copyright and in the absence of an open licence (eg Creative Commons), permissions for further reuse of content should be sought from the publisher, author or other copyright holder. Versions of research The version in the Kent Academic Repository may differ from the final published version. Users are advised to check http://kar.kent.ac.uk for the status of the paper. Users should always cite the published version of record. Enquiries For any further enquiries regarding the licence status of this document, please contact: [email protected] If you believe this document infringes copyright then please contact the KAR admin team with the take-down information provided at http://kar.kent.ac.uk/contact.html 555 Therapeutic potential of neuronal two-pore domain potassium-channel modulators Alistair Mathie* & Emma L Veale Address compounds act on these channels to alter their activity. In The Universities of Kent and Greenwich at Medway some instances, the action of these compounds may underlie Medway School of Pharmacy Central Avenue or contribute to their therapeutic activity. The physiological Chatham Maritime consequences of such activity may lead to the generation of Kent ME4 4TB compounds that selectively inhibit K2P channels for a UK particular therapeutic advantage. K2P channels can also be Email: [email protected] regulated indirectly (ie, by G-protein-coupled receptor *To whom correspondence should be addressed pathways and kinases), and thus compounds which interact with these indirect pathways also have important Current Opinion in Investigational Drugs 2007 8(7):555-562 physiological actions mediated via K2P channels. However, © The Thomson Corporation ISSN 1472-4472 it is beyond the scope of this review to also consider these indirect regulatory pathways (see reference [10] for Two-pore domain potassium (K2P) channels are expressed in cells examples). This review focuses on compounds that directly throughout the body and give rise to leak potassium currents modulate K2P channel activity, assesses the physiological which control the excitability of these cells. Although not inhibited consequences of such actions and discusses whether these by classical potassium channel-blocking drugs, such as (or any related, more selective, second-generation) tetraethylammonium and 4-aminopyridine, K2P channels are compounds provide further support for the potential regulated by a diverse array of pharmacological mediators. There targeting of K2P channels in CNS diseases such as stroke, are six main families of K2P channels and among these certain members of the TREK family (ie, TREK-1 and TREK-2) are epilepsy and depression. activated by general anesthetic agents such as halothane, xenon and nitrous oxide. In addition, all members of the TREK family General blockers of K2P channels are activated by neuroprotective agents, such as riluzole, An interesting pharmacological feature of K2P channels is polyunsaturated fatty acids and lysophospholipids, suggesting that that they are highly insensitive to both of the classical these channels play an important role in neuroprotection. TREK drugs used to block voltage-gated potassium channels: channels are also inhibited by chlorpromazine, local anesthetics tetraethylammonium (TEA) ions and 4-aminopyridine and the antidepressant fluoxetine. Furthermore, all members of the (4-AP). However, K2P channels can be blocked by barium TASK family are inhibited by cannabinoids and local anesthetics, ions and, in some cases, by quinidine and quinine. and TASK-3 is selectively inhibited by ruthenium red. Thus, the diversity and physiological importance of K2P channels suggest Quinidine and quinine that the development of selective compounds to target these Quinidine, a stereoisomer of the naturally occurring product proteins has therapeutic potential for CNS disorders such as quinine, is used as a class I anti-arrythmic agent in the heart stroke, depression and epilepsy. and affects many ion channels, including sodium, calcium and potassium channels. While quinidine blocks the TASK-1 Keywords Antidepressant, cannabinoid, ciclosporin, and TASK-3 K2P channels modestly (approximately 30% at fluoxetine, general anesthetic, lysophospholipid, neuro- 100 μM) [11-13], its effects on TREK-1 channels are more protection, polyunsaturated fatty acid, ruthenium red, two- varied. An early study of TREK-1 channels expressed in pore domain potassium channel Xenopus oocytes showed that the channels were unaffected by either quinidine or quinine [14]. However, later research Introduction with COS cells (transformed monkey kidney fibroblasts) Two-pore domain potassium (K2P) channels give rise to leak suggested that quinidine could block TREK-1 channels [15]. potassium currents and are expressed throughout the CNS Similarly, both quinine and quinidine block TWIK-2 channels [1,2] and in most other organs in the body [3•,4•,5•]. They but only when recordings are made in physiological potassium contribute to the resting membrane potential of neurons and solutions – no blockade has been observed in symmetrical regulate their excitability. While K2P channels are generally potassium solutions [16]. These latter observations highlight open at all voltages, they also display some voltage the importance of understanding the pharmacology of K2P dependency [6]. There are 15 members of the human K2P channels; the effectiveness of certain compounds is dependent channel superfamily, which can be divided into six main upon the experimental approach, and certain compounds families based on their structural and functional properties: (presumably those that interact with the permeation pathway) TREK, TASK, TWIK, TALK, THIK and TRESK (Figure 1) are influenced by the concentration and the net direction of [3•,4•,7-9]. Furthermore, K2P channels are regulated movement of the permeating ion. Of the other K2P channels, by a diverse array of pharmacological agents, TRESK [17,18] and TRAAK [19] are inhibited by both physiological mediators and neurotransmitter-activated quinidine and quinine. However, the situation for TALK pathways [3•,5•,7]. channels is more complicated. While both TALK-1 and TALK-2 channels are inhibited by quinidine (1 mM), quinine Currently, there are no compounds specifically designed to strongly inhibited TALK-1 channels and activated TALK-2 inhibit K2P channels; however, a large number of existing channels [20,21]. 556 Current Opinion in Investigational Drugs 2007 Vol 8 No 7 Figure 1. Dendrogram of the K2P channel superfamily. TASK THIK TASK-3 THIK-2 TASK-1 (K2P9.1) (K2P12.1) (K2P3.1) THIK-1 (K2P13.1) TASK-5 (K2P15.1) TRESK (K2P18.1) TRESK KCNK-7 (K2P7.1) TASK-2 TWIK-1 (K2P5.1) TWIK (K2P1.1) TALK-2 TWIK-2 (K2P17.1) TALK (K2P6.1) TALK-1 (K2P16.1) TREK-2 TRAAK (K2P10.1) TREK-1 (K2P2.1) (K2P4.1) TREK The 15 members of the K2P channel superfamily are shown according to their six main groups. The K2P nomenclature as approved by the International Union of Basic and Clinical Pharmacology is shown in parentheses (see reference [4•] for further details). Note that the KCNK-7, THIK-2 and TASK-5 subtypes are functionally silent when expressed in isolation. It is generally useful for a compound to selectively act on region is important for their anesthetic activity [23••]. In either a particular K2P channel family or an individual addition, the reduced sensitivity to volatile anesthetics in family member. The most extensively researched families of TREK-1 knockout animals [27••] suggests that the action of K2P channels are the TREK and TASK families, and as such volatile anesthetics on TREK-1 channels is of considerable this review focuses on compounds in relation to these two physiological importance. families. However, where effects of compounds have also been observed in other K2P channel families these will also Interestingly, gaseous anesthetics appear to selectively target be mentioned. and enhance the activity of TREK-1 channels (and presumably the related TREK-2 channels) with little action The TREK family of K2P channels on other K2P channels [26,28••]. The effect of these agents The TREK family (TREK-1, TREK-2 and TRAAK) is the most on TREK-1 activity was completely abolished by a single widely studied of the K2P channels and appears to show the amino-acid point mutation (ie, E306A) in the C terminus of largest diversity of regulation by pharmacological agents TREK-1 [28••], again confirming the importance of this [22]. A number of compounds have been identified which region in transducing the effect of many regulatory either upregulate or downregulate TREK channel activity, compounds on TREK-1 [29•]. The activation of TREK-1 and among these several compounds have shown important channels by gaseous anesthetic agents may also contribute to therapeutic actions, for example, as general anesthetic and their neuroprotective effects (see below and reference [26]). neuroprotective agents. Trichloroethanol (TCE; a metabolic by-product
Load more

Recommended publications
  • Effect of Hypercholesterolaemia on Voltage-Operated Calcium Channel Currents in Rabbit Arterial Smooth Muscle Cells
    Journal of Human Hypertension (1999) 13, 849–853 1999 Stockton Press. All rights reserved 0950-9240/99 $15.00 http://www.stockton-press.co.uk/jhh Effect of hypercholesterolaemia on voltage-operated calcium channel currents in rabbit arterial smooth muscle cells GF Clunn, S Wijetunge and AD Hughes Clinical Pharmacology, NHLI, St. Mary’s Hospital, Imperial College of Science, Technology and Medicine, South Wharf Road, London, W2 1NY, UK Cholesterol is a major component of cell membranes capacitance was also greater in NZ cells. Consequently, and influences membrane fluidity. Watanabe heritable there was no significant difference in current density hyperpercholesterolaemic rabbits (WHHL) possess between NZ and WHHL cells either in the absence of defective receptors for low density lipoprotein leading drug or in the presence of the calcium channel agonist to increased plasma cholesterol, accumulation of chol- (+)202 791. Current voltage-relationships, kinetics of esterol in the arterial wall and atherosclerosis. In this fast inactivation and steady-state inactivation of IBa also study calcium channel currents (IBa) were compared did not differ significantly between WHHL and NZ. These using conventional whole cell voltage clamp techniques findings suggest that hypercholesterolaemia in WHHL in ear artery cells isolated from control New Zealand has no direct effect on calcium channel current density White rabbits (NZ) with those from WHHL. IBa were larger or voltage-modulation in arterial smooth muscle cells. in cells isolated from NZ than from WHHL, however cell Keywords: calcium channel; cholesterol; vascular smooth muscle; Watanabe hypercholesterolaemic rabbit Introduction atic cholesterol toxicity or other organ damage which develops in cholesterol-fed rabbits.15 WHHL Cholesterol is a major component of cell membranes 1,2 has therefore been proposed to be a model of human and influences membrane structure and fluidity.
    [Show full text]
  • Mepivacaine Hydrochloride Injection
    POLOCAINE- mepivacaine hydrochloride injection, solution Dentsply Pharmaceutical ---------- 3% Polocaine® DENTAL Mepivacaine Hydrochloride 3% (30 mg/mL) (Mepivacaine Hydrochloride Injection, USP) 2% Polocaine® DENTAL with Levonordefrin 1:20,000 Mepivacaine Hydrochloride 2% (20 mg/mL) with Levonordefrin 1:20,000 (Mepivacaine Hydrochloride and Levonordefrin Injection, USP) Rx Only THESE SOLUTIONS ARE INTENDED FOR DENTAL USE ONLY. DESCRIPTION Mepivacaine Hydrochloride, a tertiary amine used as a local anesthetic, is 1-methyl-2,' 6' - pipecoloxylidide monohydrochloride with the following structural formula: It is a white, crystalline, odorless powder soluble in water, but very resistant to both acid and alkaline hydrolysis. Levonordefrin, a sympathomimetic amine used as a vasoconstrictor in local anesthetic solution, is (-)-α-(1-Aminoethyl)-3, 4-dihydroxybenzyl alcohol with the following structural formula: It is a white or buff-colored crystalline solid, freely soluble in aqueous solutions of mineral acids, but practically insoluble in water. DENTAL CARTRIDGES MAY NOT BE AUTOCLAVED. 3% (30 mg/mL) Polocaine® DENTAL (mepivacaine hydrochloride injection 3% (30 mg/mL)) and 2% (20 mg/mL) Polocaine® DENTAL with Levonordefrin 1:20,000 (mepivacaine hydrochloride 2% (20 mg/mL) with levonordefrin 1:20,000 injection) are sterile solutions for injection. sterile solutions for injection. COMPOSITION: CARTRIDGE Each mL contains: 2% 3% Mepivacaine Hydrochloride 20 mg 30 mg Levonordefrin 0.05 mg - Sodium Chloride 4 mg 6 mg Potassium metabisulfite 1.2 mg - Edetate disodium 0.25 mg - Sodium Hydroxide q.s. ad pH; Hydrochloric 0.5 mg - Acid Water For Injection, qs. ad. 1 mL 1 mL The pH of the 2% cartridge solution is adjusted between 3.3 and 5.5 with NaOH.
    [Show full text]
  • 4% Citanest® Plain Dental (Prilocaine Hydrochloride Injection, USP) for Local Anesthesia in Dentistry
    4% Citanest® Plain Dental (Prilocaine Hydrochloride Injection, USP) For Local Anesthesia in Dentistry Rx only DESCRIPTION 4% Citanest Plain Dental (prilocaine HCI Injection, USP), is a sterile, non-pyrogenic isotonic solution that contains a local anesthetic agent and is administered parenterally by injection. See INDICATIONS AND USAGE for specific uses. The quantitative composition is shown in Table 1. 4% Citanest Plain Dental contains prilocaine HCl, which is chemically designated as propanamide, N-(2- methyl-phenyl) -2- (propylamino)-, monohydrochloride and has the following structural formula: Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. The specific quantitative composition is shown in Table 1. TABLE 1. COMPOSITION Product Identification Formula (mg/mL) Prilocaine HCl pH 4% Citanest® Plain Dental 40.0 6.0 to 7.0 Note: Sodium hydroxide or hydrochloric acid may be used to adjust the pH of 4% Citanest Plain Dental Injection. CLINICAL PHARMACOLOGY Mechanism of Action: Prilocaine stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthetic action. Onset and Duration of Action: When used for infiltration injection in dental patients, the time of onset of anesthesia averages less than 2 minutes with an average duration of soft tissue anesthesia of approximately 2 hours. Based on electrical stimulation studies, 4% Citanest Plain Dental Injection provides a duration of pulpal anesthesia of approximately 10 minutes in maxillary infiltration injections. In clinical studies, this has been found to provide complete anesthesia for procedures lasting an average of 20 minutes. When used for inferior alveolar nerve block, the time of onset of 4% Citanest Plain Dental Injection averages less than three minutes with an average duration of soft tissue anesthesia of approximately 2 ½hours.
    [Show full text]
  • Local Anesthetic Half Life (In Hours) Lidocaine 1.6 Mepivacaine 1.9 Bupivacaine 353.5 Prilocaine 1.6 Articaine 0.5
    Local Anesthetics • The first local anesthetics History were cocaine and procaine (Novacain) developed in ltlate 1800’s • They were called “esters” because of their chemical composition • Esters had a slow onset and short half life so they did not last long History • Derivatives of esters called “amides” were developed in the 1930’s • Amides had a faster onset and a longer half life so they lasted longer • AidAmides quiklickly repldlaced esters • In dentistry today, esters are only found in topical anesthetics Generic Local Anesthetics • There are five amide anesthetics used in dentistry today. Their generic names are; – lidocaine – mepivocaine – bupivacaine – prilocaine – artica ine • Each is known by at least one brand name Brand Names • lidocaine : Xylocaine, Lignospan, Alphacaine, Octocaine • mepivocaine: Carbocaine, Arestocaine, Isocaine, Polocaine, Scandonest • prilocaine : Citanest, Citanest Forte • bibupivaca ine: MiMarcaine • articaine: Septocaine, Zorcaine About Local Anesthetic (LA) • Local anesthetic (LA) works by binding with sodium channels in neurons preventing depolarization • LA is inactivated at the injection site when it is absorbed into the blood stream and redistributed throughout the body • If enough LA is absorbed, sodium channels in other parts of the body will be blocked, causing systemic side effects About LA • A clinical effect of LAs is dilation blood vessels, speeding up absorption and distribution • To counteract this dilation so anesthesia is prolonged, , a vasoconstrictor is often added to LAs • However, vasoconstrictors have side effects also Metabolism and Excretion • Most amide LAs are metabolized (inactivated) by the liver and excreted by the kidneys. • Prilocaine is partially metabolized by the lungs • Articaine is partially metabolized by enzymes in the bloo d as well as the liver.
    [Show full text]
  • Hyperinflation Management Medications Requiring Prior Authorization for Medical Necessity
    July 2021 Effective 07/01/2021 Hyperinflation Management Medications Requiring Prior Authorization for Medical Necessity Below is a list of medicines by drug class that will not be covered without a prior authorization for medical necessity. If you continue using one of these drugs without prior approval for medical necessity, you may be required to pay the full cost. If you are currently using one of the drugs requiring prior authorization for medical necessity, ask your d octor to choose one of the generic or brand formulary options listed below. Category * Drugs Requiring Prior Formulary Options Drug Class Authorization for Medical Necessity 1 Allergies Dexchlorpheniramine levocetirizine Antihistamines Diphen Elixir (NDC^ 69067009204 only) RyClora CARBINOXAMINE TABLET 6 MG Anti-convulsants topiramate ext-rel capsule carbamazepine, carbamazepine ext-rel, (generics for QUDEXY XR only) clobazam, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, rufinamide, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI XR, VIMPAT, XCOPRI ZONEGRAN carbamazepine, carbamazepine ext-rel, divalproex sodium, divalproex sodium ext-rel, gabapentin, lamotrigine, lamotrigine ext-rel, levetiracetam, levetiracetam ext-rel, oxcarbazepine, phenobarbital, phenytoin, phenytoin sodium extended, primidone, tiagabine, topiramate, valproic acid, zonisamide, FYCOMPA, OXTELLAR XR, TROKENDI
    [Show full text]
  • Calcium Channel Blocker As a Drug Candidate for the Treatment of Generalised Epilepsies
    UNIVERSITAT DE BARCELONA Faculty of Pharmacy and Food Sciences Calcium channel blocker as a drug candidate for the treatment of generalised epilepsies Final degree project Author: Janire Sanz Sevilla Bachelor's degree in Pharmacy Primary field: Organic Chemistry, Pharmacology and Therapeutics Secondary field: Physiology, Pathophysiology and Molecular Biology March 2019 This work is licensed under a Creative Commons license ABBREVIATIONS AED antiepileptic drug AMPA α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid ANNA-1 antineuronal nuclear antibody 1 BBB blood-brain barrier Bn benzyl BnBr benzyl bromide BnNCO benzyl isocyanate Boc tert-butoxycarbonyl Bu4NBr tetrabutylammonium bromide Ca+2 calcium ion CACNA1 calcium channel voltage-dependent gene cAMP cyclic adenosine monophosphate CCB calcium channel blocker cGMP cyclic guanosine monophosphate CH3CN acetonitrile Cl- chlorine ion Cmax maximum concentration CMV cytomegalovirus CTScan computed axial tomography DCM dichloromethane DIPEA N,N-diisopropylethylamine DMF dimethylformamide DMPK drug metabolism and pharmacokinetics DNET dysembryoplastic neuroepithelial tumours EEG electroencephalogram EPSP excitatory post-synaptic potential FDA food and drug administration Fe iron FLIPR fluorescence imaging plate reader fMRI functional magnetic resonance imaging GABA γ-amino-α-hydroxybutyric acid GAD65 glutamic acid decarboxylase 65 GAERS generalised absence epilepsy rat of Strasbourg GluR5 kainate receptor GTC generalised tonic-clonic H+ hydrogen ion H2 hydrogen H2O dihydrogen dioxide (water)
    [Show full text]
  • The Role of Excitotoxicity in the Pathogenesis of Amyotrophic Lateral Sclerosis ⁎ L
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1762 (2006) 1068–1082 www.elsevier.com/locate/bbadis Review The role of excitotoxicity in the pathogenesis of amyotrophic lateral sclerosis ⁎ L. Van Den Bosch , P. Van Damme, E. Bogaert, W. Robberecht Neurobiology, Campus Gasthuisberg O&N2, PB1022, Herestraat 49, B-3000 Leuven, Belgium Received 21 February 2006; received in revised form 4 May 2006; accepted 10 May 2006 Available online 17 May 2006 Abstract Unfortunately and despite all efforts, amyotrophic lateral sclerosis (ALS) remains an incurable neurodegenerative disorder characterized by the progressive and selective death of motor neurons. The cause of this process is mostly unknown, but evidence is available that excitotoxicity plays an important role. In this review, we will give an overview of the arguments in favor of the involvement of excitotoxicity in ALS. The most important one is that the only drug proven to slow the disease process in humans, riluzole, has anti-excitotoxic properties. Moreover, consumption of excitotoxins can give rise to selective motor neuron death, indicating that motor neurons are extremely sensitive to excessive stimulation of glutamate receptors. We will summarize the intrinsic properties of motor neurons that could render these cells particularly sensitive to excitotoxicity. Most of these characteristics relate to the way motor neurons handle Ca2+, as they combine two exceptional characteristics: a low Ca2+-buffering capacity and a high number of Ca2+-permeable AMPA receptors. These properties most likely are essential to perform their normal function, but under pathological conditions they could become responsible for the selective death of motor neurons.
    [Show full text]
  • Ep 1931310 B1
    (19) & (11) EP 1 931 310 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/12 (2006.01) A61K 9/06 (2006.01) 06.06.2012 Bulletin 2012/23 A61K 9/70 (2006.01) A61K 47/32 (2006.01) A61K 47/24 (2006.01) A61K 47/10 (2006.01) (21) Application number: 06779420.6 (86) International application number: (22) Date of filing: 14.09.2006 PCT/GB2006/003408 (87) International publication number: WO 2007/031753 (22.03.2007 Gazette 2007/12) (54) Monophasic film-forming composition for topical administration Monophasische filmbildende Zusammensetzung zum topischen Auftrag Composition monophase formant un film pour l’administration à voie topique (84) Designated Contracting States: • JONES, Stuart, Allen AT BE BG CH CY CZ DE DK EE ES FI FR GB GR London SE3 0XA (GB) HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR (74) Representative: Lord, Hilton David Marks & Clerk LLP (30) Priority: 14.09.2005 GB 0518769 90 Long Acre London (43) Date of publication of application: WC2E 9RA (GB) 18.06.2008 Bulletin 2008/25 (56) References cited: (73) Proprietor: Medpharm Limited WO-A2-01/43722 US-A- 4 752 466 Charlbury, US-A- 4 863 721 US-A1- 2004 184 994 Oxfordshire OX7 3RR (GB) US-A1- 2004 213 744 (72) Inventors: • BROWN, Marc, Barry Hertfordshire WD19 4QQ (GB) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Repurposing Potential of Riluzole As an ITAF Inhibitor in Mtor Therapy Resistant Glioblastoma
    International Journal of Molecular Sciences Article Repurposing Potential of Riluzole as an ITAF Inhibitor in mTOR Therapy Resistant Glioblastoma Angelica Benavides-Serrato 1, Jacquelyn T. Saunders 1 , Brent Holmes 1, Robert N. Nishimura 1,2, Alan Lichtenstein 1,3,4 and Joseph Gera 1,3,4,5,* 1 Department of Research & Development, Greater Los Angeles Veterans Affairs Healthcare System, Los Angeles, CA 91343, USA; [email protected] (A.B.-S.); [email protected] (J.T.S.); [email protected] (B.H.); [email protected] (R.N.N.); [email protected] (A.L.) 2 Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA 3 Jonnson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA 90095, USA 4 Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095, USA 5 Molecular Biology Institute, University of California-Los Angeles, Los Angeles, CA 90095, USA * Correspondence: [email protected]; Tel.: +00-1-818-895-9416 Received: 12 December 2019; Accepted: 31 December 2019; Published: 5 January 2020 Abstract: Internal ribosome entry site (IRES)-mediated protein synthesis has been demonstrated to play an important role in resistance to mechanistic target of rapamycin (mTOR) targeted therapies. Previously, we have demonstrated that the IRES trans-acting factor (ITAF), hnRNP A1 is required to promote IRES activity and small molecule inhibitors which bind specifically to this ITAF and curtail IRES activity, leading to mTOR inhibitor sensitivity. Here we report the identification of riluzole (Rilutek®), an FDA-approved drug for amyotrophic lateral sclerosis (ALS), via an in silico docking analysis of FDA-approved compounds, as an inhibitor of hnRNP A1.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • An Advanced Drug Delivery System Targeting Brain Through BBB
    pharmaceutics Review Solid Lipid Nanoparticles (SLNs): An Advanced Drug Delivery System Targeting Brain through BBB Mantosh Kumar Satapathy 1 , Ting-Lin Yen 1,2,† , Jing-Shiun Jan 1,†, Ruei-Dun Tang 1,3, Jia-Yi Wang 3,4,5 , Rajeev Taliyan 6 and Chih-Hao Yang 1,5,* 1 Department of Pharmacology, School of Medicine, College of Medicine, Taipei Medical University, No. 250, Wu Hsing St., Taipei 110, Taiwan; [email protected] (M.K.S.); [email protected] (T.-L.Y.); [email protected] (J.-S.J.); [email protected] (R.-D.T.) 2 Department of Medical Research, Cathay General Hospital, Taipei 22174, Taiwan 3 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University, No. 250, Wu Hsing St., Taipei 110, Taiwan; [email protected] 4 Department of Neurosurgery, Taipei Medical University Hospital, Taipei 110, Taiwan 5 Neuroscience Research Center, Taipei Medical University, Taipei 110, Taiwan 6 Department of Pharmacy, Neuropsychopharmacology Division, Birla Institute of Technology and Science, Pilani 333031, India; [email protected] * Correspondence: [email protected]; Tel.: +886-2-2736-1661 (ext. 3197) † These authors contributed equally to this work. Abstract: The blood–brain barrier (BBB) plays a vital role in the protection and maintenance of homeostasis in the brain. In this way, it is an interesting target as an interface for various types of drug delivery, specifically in the context of the treatment of several neuropathological conditions where the therapeutic agents cannot cross the BBB. Drug toxicity and on-target specificity are among Citation: Satapathy, M.K.; Yen, T.-L.; some of the limitations associated with current neurotherapeutics.
    [Show full text]
  • Meta-Xylene: Identification of a New Antigenic Entity in Hypersensitivity
    Clinical Communications Meta-xylene: identification of a new Our patient is a 53-year-old male who presented in 2003 with antigenic entity in hypersensitivity contact dermatitis after the use of lidocaine and disinfection with reactions to local anesthetics chlorhexidine. In 2006, an extensive skin testing by patch, prick, Kuntheavy Ing Lorenzini, PhDa, intradermal sampling, and graded challenge was performed as b c followed. The patch tests were performed with the thin layer Fabienne Gay-Crosier Chabry, MD , Claude Piguet, PhD , rapid use epicutaneous test, using the caine mix (benzocaine, a and Jules Desmeules, MD tetracaine, and cinchocaine), the paraben mix (methyl, ethyl, propyl, butyl, and benzylparaben), and the Balsam of Peru. The Clinical Implications caine and paraben mix were positive, and the patch test was possibly positive for Balsam of Peru. The prick test performed The authors report a patient who presented delayed with preservative-free lidocaine 20 mg/mL (Lidocaïne HCl hypersensitivity reactions to several local anesthetics, all “Bichsel” 2%, Grosse Apotheke Dr. G. Bichsel, Switzerland) was containing a meta-xylene entity, but not to articaine, negative. The intradermal test, performed with lidocaine 20 mg/ which is a thiophene derivative. Meta-xylene could be the mL containing methylparaben (Xylocain 2%, AstraZeneca, immunogenic epitope. Switzerland) with 1/10 and 1/100 dilutions, was negative. The subcutaneous challenge test was performed with 10 mg of preservative-free lidocaine 20 mg/mL (Lidocaïne HCl “Bichsel” TO THE EDITOR: 2%, Grosse Apotheke Dr. G. Bichsel) and lidocaine 20 mg/mL containing methylparaben (Lidocaïne Streuli 2%, Streuli, Hypersensitivity reactions to local anesthetics (LAs) are rare and Switzerland), both of which were positive and had the appear- represent less than 1% of all adverse reactions to LAs.
    [Show full text]